Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as 2-11-2024, 02:00

Colliers joins the World Green Building Council’s Net Zero Carbon Buildings Commitment 7-12-2023, 19:15

Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner 25-03-2024, 19:00